Evommune, Inc. (EVMN) Stock

NYSE: EVMNHealthcare company in the biotechnology industry, based in Palo Alto, CA.

Evommune stock price chart

EVMN interactive chart →

EVMN stock quote & key statistics

Evommune earnings per share

Income →
Earnings per share

Evommune revenue & net income

Income →
RevenueNet income

Evommune annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$13.0M-$68.9M-$9.50
FY2024$7.0M-$66.8M—
FY2023$5.0M-$34.1M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Evommune stock FAQ

What is the Evommune stock ticker symbol?

Evommune, Inc. trades on the NYSE under the ticker symbol EVMN.

What sector and industry is Evommune in?

Evommune, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Evommune have?

Evommune, Inc. has about 48 full-time employees.

What were Evommune's revenue and earnings last fiscal year?

Evommune reported revenue of $13.0M and net income of -$68.9M in fiscal 2025, with earnings per share of -$9.50. Revenue grew 85.7% from the prior year.

Is Evommune in the Russell 2000?

Yes. Evommune, Inc. (EVMN) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Evommune go public?

Evommune stock began trading on November 6, 2025.

Russell 2000 Biotechnology stocks

All Russell 2000 →